Association of the UGT1A1-53(TA)n polymorphism with L-thyroxine doses required for thyrotropin suppression in patients with differentiated thyroid cancer.

Vargens, Daniela D; Neves, Ronaldo R S; Bulzico, Daniel A; Ojopi, Elida B; Meirelles, Ricardo M R; Pessoa, Cencita N; Prado, Carolina M; Gonçalves, Pedro A; Leal, Vera L G; Suarez-Kurtz, Guilherme

Vargens, Daniela D; Neves, Ronaldo R S; Bulzico, Daniel A; Ojopi, Elida B; Meirelles, Ricardo M R; Pessoa, Cencita N; Prado, Carolina M; Gonçalves, Pedro A; Leal, Vera L G; Suarez-Kurtz, Guilherme.

Affiliation

Vargens DD; Divisão de Farmacologia, Instituto Nacional de Câncer, São Paulo, Brazil.

Pharmacogenet Genomics ; 21(6): 341-3, 2011 Jun.

Article in En | MEDLINE | ID: mdl-21317830

Subject(s)

Cell Differentiation; Glucuronosyltransferase/genetics; Polymorphism, Genetic/genetics; Thyroid Neoplasms/drug therapy; Thyroid Neoplasms/genetics; Thyroxine/therapeutic use; Alleles; DNA, Neoplasm/genetics; Genotype; Humans; Polymerase Chain Reaction; Thyroid Neoplasms/pathology; Thyrotropin

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polymorphism, Genetic / Thyroxine / Thyroid Neoplasms / Cell Differentiation / Glucuronosyltransferase Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Pharmacogenet Genomics Journal subject: FARMACOLOGIA / GENETICA MEDICA Year: 2011 Document type: Article Affiliation country: Brazil

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google